| True positive n (%) | False negative n (%) | False positive n (%) | True negative n (%) | Sensitivity (95% CI) | Specificity (95% CI) | NPV | Total | p-value |
Age group in years |
|
|
|
|
|
|
|
| |
20 - 29 | 53 (100.0) | 11 (4.8) | 0 (0.0) | 218 (95.2) | 82.8 (71.3 - 100.0) | 100 (98.3 - 100.0 | 95.2 (95.1 - 97.1 | 282 | <0.001 |
30 - 39 | 8 (100.0) | 5 (14.3) | 0 (0.0) | 30 (85.7) | 61.5 (31.6 - 86.1) | 100 (88.4 - 100.0) | 85.7 (75.1 - 92.3) | 43 | <0.001* |
≥40 | 7 (100.0) | 3 (15.8) | 0 (0.0) | 16 (84.2) | 70.0 (34.8 - 93.3) | 100.0 (79.4 - 100.0) | 84.2 (67.4 - 93.2 | 26 | <0.001* |
Gender |
|
|
|
|
|
|
|
|
|
Male | 49 (100.0) | 11 (94.7) | 0 (0.0) | 151 (93.2) | 81.7 (69.6 - 90.5) | 100.0 (97.6 - 100.0) | 93.2 (88.9 - 95.9) | 211 | <0.001 |
Female | 19 (100.0) | 8 (6.6) | 0 (0.0) | 113 (93.4) | 70.4 (49.8 - 86.3) | 100.0 (96.8 - 100.0) | 93.4 (88.8 - 96.2) | 140 | <0.001 |
Period of test |
|
|
|
|
|
|
|
|
|
January, 2021 | 37 (100.0) | 14 (8.2) | 0 (0.0) | 156 (91.8) | 72.6 (58.3 - 84.1) | 100.0 (97.78 - 100.00) | 98.80 (97.7 - 100.0) | 207 | <0.001* |
March, 2021 | 31 (100.0) | 5 (4.4) | 0 (0.0) | 107 (85.6) | 86.1 (70.5 - 95.3) | 100.0 (96.6 - 100.0) | 95.5 (90.5- 97.9 | 144 | <0.001* |
Symptomatic |
|
|
|
|
|
|
|
|
|
Yes | 11 (100.0) | 3 (4.8) | 0 (0.0) | 59 (95.2) | 78.6 (49.2 - 95.3) | 100.0 (93.9 - 100.0) | 95.2 (87.8 - 98.2) | 73 | 0.002* |
No | 57 (100.0%) | 16 (7.2) | 0 (0.0) | 205 (92.8) | 78.1 (66.9 - 86.9) | 100.0 (98.2 - 100.00) | 92.8 (89.3 - 95.2) | 278 | <0.001* |